Breakthrough Study Links TYK2 Enzyme to Alzheimer's Progression and Neuroinflammation

Scientists have uncovered a key enzyme linked to neuroinflammation in Alzheimer's disease (AD) patients with TDP-43 protein clumps. The enzyme, called TYK2, worsens brain tissue damage when overactive in immune cells known as microglia. This discovery opens new possibilities for targeted treatments.

Higher levels of soluble TYK2 in patients' cerebrospinal fluid have been tied to faster cognitive decline and more severe disease progression. The findings suggest that controlling TYK2 activity could help slow AD in those with TDP-43 pathology.

The study used spatial transcriptomics to map molecular changes in brain tissue. This technology revealed how TYK2 activation in microglia triggers harmful inflammatory responses. Researchers found that TYK2 switches on STAT1 and STAT3 pathways, which control genes involved in immune reactions and cell stress.

Experiments in mouse models showed that removing TYK2 reduced inflammation and protected neurons from damage. When treated with small-molecule TYK2 inhibitors, microglia returned to a balanced state, shielding cultured neurons from inflammatory harm. These results indicate that blocking TYK2 could limit brain damage without weakening the immune system. Existing drugs like Tofacitinib, Upadacitinib, Baricitinib, and Ritlecitinib—currently used for rheumatoid arthritis and other inflammatory conditions—may provide a foundation for developing TYK2-specific therapies. Since AD often involves multiple overlapping pathologies, the team stressed the need for precision medicine approaches that combine or sequence treatments. Beyond Alzheimer's, these insights could apply to other neurodegenerative diseases where TDP-43 builds up. Understanding TYK2's role may lead to broader therapeutic strategies for conditions with similar inflammatory mechanisms.

The research highlights TYK2 as a promising target for Alzheimer's patients with TDP-43 pathology. Inhibitors designed to block this enzyme could offer a way to reduce neuroinflammation while avoiding systemic side effects. Further studies will determine whether repurposed or new TYK2 drugs can slow cognitive decline in affected individuals.